Haval Ozgun, recently appointed to an expanded role at South West London Pathology (SWLP), is set to lead the organisation into a new era of rapid diagnostics and business development. As the newly designated General Manager for the Rapid Diagnostics and POCT, Haval has ambitious plans to transform SWLP into a leader in innovative diagnostic services, while maintaining the highest standards of patient care.
In his new role, Haval will focus on integrating business development with SWLP’s established diagnostic services, a move that he sees as a natural progression of his career. “This role allows me to blend my clinical expertise with strategic growth initiatives,” he said.
“My career has always been centred on enhancing healthcare delivery through innovative diagnostics, and this role gives me the opportunity to push that vision further.”
One of Haval’s primary objectives is to diversify SWLP’s revenue streams by exploring new markets, both within the NHS and the private sector. He aims to expand SWLP’s footprint into private hospitals, GP practices, and develop home-sampling services.
“We’ll be building strategic partnerships with reputable pathology suppliers and focusing on customer care excellence,”
Haval explained.
“By aligning our business development efforts with our clinical mission, we can achieve sustainable growth that benefits both our organisation and the patients we serve.”
Leadership, according to Haval, is about creating a shared vision and empowering his team to achieve it. He plans to foster a culture of collaboration and innovation within SWLP, ensuring that every team member understands their role in the broader mission.
“We’re entering a period of significant change, particularly with the integration of ESTH POCT under SWLP,”
he said.
“My focus will be on guiding the team through these transitions with clarity and support, while maintaining a patient-centric approach.”
The integration of the POCT services from Epsom and St Helier University Hospitals NHS Trust (ESTH) under SWLP in (date), which were initially out of scope with ESTH joined the SWLP partnership, is seen as a significant milestone. Haval believes this will greatly enhance the quality and reach of SWLP’s services.
“This integration allows us to standardise practices across sites, ensuring that all patients receive the same high standard of care, It will also enable us to streamline our operations and improve our response times.
Haval continued,
“Effective communication, empathy, and a focus on customer and patient satisfaction are key to ensuring that our growth is sustainable and that our services continue to meet the highest standards of care.”
Looking to the future, Haval envisions rapid diagnostics playing a crucial role in expanding accessibility and integrating advanced technologies into everyday care. He sees significant growth potential in home-testing and self-sampling services, especially for managing long-term conditions like diabetes.
“The ability to offer testing at the point of need, whether in a community setting or a patient’s home, will be crucial,”
he said.
“We’re also focused on enhancing the clinical applications of rapid diagnostics across primary and secondary care settings, ensuring that our services are not only efficient but also of the highest clinical standard.”
